Table 3.
A summary of operative details for patients who underwent neoadjuvant immunotherapy in the treatment of resectable non-small cell lung cancer.
| Resection Margin | Type of Surgery | Surgical Approach | Final Immunotherapy to Surgery | Blood Loss | ||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Study | R0 | R1 | R2 | Pneumonectomy | Bilobectomy | Lobectomy | Sleeve Lobectomy |
Wedge | Other | Exploratory | Thoracotomy | MIS | Conversion to Open | Median Days | Delay (n) | Time (min) | Blood Loss (mL) | Transfusion |
| Rothschild [5] | 51 | 3 | 1 | 5 | 7 | 43 | - | - | - | - | - | - | - | - | - | - | - | - |
| Provencio [6], Roman [7] |
41 | 0 | 0 | 3 | 3 | 32 | 3 | 0 | - | 0 | 24/41 | 17/41 | 4/41 | - | 0 | 195 | - | 1 |
| Cascone [8] | 39 | 0 | 0 | - | - | - | - | - | - | - | - | - | - | 31 | 8 | - | - | - |
| Eicchorn [9] | 15 | 0 | 0 | 0 | 0 | 15 | 0 | 0 | - | 0 | - | - | - | - | 1 | - | - | - |
| Tong [10] | 22 | 3 | 0 | 3 | 1 | 18 | 2 | - | 1 | - | 7/25 | 18/25 | 5/25 | 26 | 1 | 305 | - | 2 |
| Shu [11] | 26 | - | - | 3 | 4 | 19 | 0 | 0 | - | 3 | 14/29 | 12/29 | - | 27 | 0 | - | - | 2 |
| Bott [12] Forde [13] |
20 | - | - | 2 | 1 | 15 | 1 | 1 | - | - | 14/20 | 6/20 | 7/20 | 18 | 0 | 228 | 100 | - |
| Gao [14] | 36 | 0 | 1 | 13 | 5 | 18 | 1 | 0 | - | 2 | 29/39 | 10/39 | - | - | 2 | - | - | - |
| Yang [15] | 13 | 0 | 0 | 1 | 1 | 10 | 0 | 1 | - | - | 4/13 | 9/13 | 3/13 | - | 2 | - | - | 2 |
| Wang [16] | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 0 | - | - | - |
| Shen [17] | 37 | 0 | 0 | 2 | 7 | 22 | 6 | - | - | - | 12/37 | 25/37 | - | - | - | 184 | - | - |
| Jiang [18] | 24 | 4 | 3 | 2 | 4 | 18 | 7 | 0 | 0 | 0 | 23/31 | 8/31 | 1 | 34 | - | 158 | 200 | 2 |
| Huang [19] | 23 | 1 | 0 | 1 | 3 | 19 | - | - | 1 | - | 0/24 | 24/24 | - | 29 | 0 | 196 | 92 | - |
| Duan [20] | 19 | 1 | 0 | 2 | 2 | 11 | 5 | 0 | - | 0 | 6/20 | 14/20 | 2/20 | - | - | 250 | 212.5 | 2 |
| Chen [21] | 12 | 0 | 0 | 0 | 1 | 8 | 3 | 0 | - | 0 | 9/12 | 3/12 | - | 28 | 1 | 140 | 200 | - |
| Chen [22] | 35 | 0 | 0 | 3 | 9 | 9 | - | - | 14 # | - | 34/35 | 1/35 | - | 33 | 0 | - | - | - |
| Overall | 97.3% | 1.7% | 0.6% | 8.6% | 12.1% | 67.5% | 7.8% | 0.9% | 5.0% | 1.4% | 51.7% | 47.4% | 12.4% | IQR (27– 32) | 2.0% | IQR (171–239) | 96–207 | 6.9% |
Duration from last dose of immunotherapy; # included sleeve and Pancoast tumor resections; IQR, Interquartile range; MIS, minimally invasive surgery.